← Leaderboards
Wenzhen Duan
Johns Hopkins University
$10,264,448
Attributed
$12,355,914
Total exposure
14
Grants
12
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants.
Funding over time
peak $1.6M · FY2007–25$2M$1.5M$1M$500K$0
'07
'08
'09
'10
'11
'12
'13
'14
'15
'16
'17
'18
'19
'20
'21
'22
'23
'24
'25
Funding mix
By agency
NIH$12,355,914 · 14
By mechanism
R01$7,886,487 · 4
R21$3,947,036 · 9
R56$522,391 · 1
Top collaborators
- Sarah A Woodson5 shared
- Jiadi Xu4 shared
- Jun Hua2 shared
Most similar at Johns Hopkins University
Same institution · by research overlap
- Anish Bhardwaj$1,777,320
- Sarah A Woodson$16,306,396
- Pan Li$4,694,846
- Henry M Colecraft$18,758,281
- Thomas L Shirley$102,476
Others in their field
Top investigators on “Huntington Disease”
- Jane S Paulsen · University Of Wisconsin-Madison$59,478,283
- Steven M Finkbeiner · J. David Gladstone Institutes$27,959,245
- Steven M Hersch · Emory University$23,594,084
- Lisa M. Ellerby · Buck Institute For Age Research$23,180,615
- Peggy C Nopoulos · University Of Iowa$21,784,331
- Christopher A Ross · Johns Hopkins University$20,194,349
Research focus
Huntington DiseaseBrainMutantMouse ModelNeurodegenerative DisordersPreventDisease ProgressionHuntington GeneLengthMagnetic Resonance ImagingNeuronsResponseCerebral AtrophyIn VivoBaseToxic EffectImpairmentMotorClinical TrialsGenesNerve DegenerationPathologyMonitorCorpus Striatum Structure
Grant awards (35)
Advanced MRI biomarkers in HD mouse models translatable to humans: nature history and response to therapeutics$628,127
R01 · FY2025 · NS · contact PI
Emerging role of glymphatic clearance in Huntington's disease$455,052
R01 · FY2025 · NS · contact PI
Advanced MRI biomarkers in HD mouse models translatable to humans: nature history and response to therapeutics$622,389
R01 · FY2024 · NS · contact PI
Emerging role of glymphatic clearance in Huntington's disease$497,183
R01 · FY2024 · NS · contact PI
Advanced MRI biomarkers in HD mouse models translatable to humans: nature history and response to therapeutics$649,989
R01 · FY2023 · NS · contact PI
Emerging role of glymphatic clearance in Huntington's disease$530,538
R01 · FY2023 · NS · contact PI
Developing HTS assays for identifying NLK activators to target Huntington's disease$450,313
R21 · FY2023 · NS · contact PI
Advanced MRI biomarkers in HD mouse models translatable to humans: nature history and response to therapeutics$684,505
R01 · FY2022 · NS · contact PI
Advanced MRI biomarkers in HD mouse models translatable to humans: nature history and response to therapeutics$522,391
R56 · FY2021 · NS · contact PI
Imaging brain glucose uptake by onVDMP MRI in Huntington's Disease$464,604
R21 · FY2020 · NS · contact PI
Structure of Triplet Repeat mRNA in Neurodegenerative Disease$358,203
R01 · FY2020 · NS
Structure of Triplet Repeat mRNA in Neurodegenerative Disease$358,203
R01 · FY2019 · NS
Cerebrovascular Abnormalities in Huntington's Disease$203,094
R21 · FY2019 · NS
Structure of Triplet Repeat mRNA in Neurodegenerative Disease$358,203
R01 · FY2018 · NS
Cerebrovascular Abnormalities in Huntington's Disease$243,360
R21 · FY2018 · NS
Huntington's disease biomarkers and therapeutics$384,151
R01 · FY2017 · NS · contact PI
Structure of Triplet Repeat mRNA in Neurodegenerative Disease$357,747
R01 · FY2017 · NS
NG2 cells in Huntington's disease$243,000
R21 · FY2017 · NS · contact PI
Mitochondrial SIRT3 in Huntington's disease$204,427
R21 · FY2017 · NS · contact PI
Huntington's disease biomarkers and therapeutics$389,332
R01 · FY2016 · NS · contact PI
Structure of Triplet Repeat mRNA in Neurodegenerative Disease$356,745
R01 · FY2016 · NS
Mitochondrial SIRT3 in Huntington's disease$244,625
R21 · FY2016 · NS · contact PI
NG2 cells in Huntington's disease$202,500
R21 · FY2016 · NS · contact PI
Huntington's disease biomarkers and therapeutics$395,911
R01 · FY2015 · NS · contact PI
Huntington's Disease biomarkers and therapeutics$37,704
R01 · FY2015 · NS · contact PI
Huntington's disease biomarkers and therapeutics$398,334
R01 · FY2014 · NS · contact PI
Huntington's disease biomarkers and therapeutics$424,171
R01 · FY2013 · NS · contact PI
Preclinical neuroprotective trials of a PPAR-gamma agonist in HD mouse models$246,000
R21 · FY2012 · NS · contact PI
Validation of structural MRI as a biomarker in Huntington's disease$246,000
R21 · FY2012 · NS · contact PI
Validation of structural MRI as a biomarker in Huntington's disease$205,000
R21 · FY2011 · NS · contact PI
Preclinical neuroprotective trials of a PPAR-gamma agonist in HD mouse models$205,000
R21 · FY2011 · NS · contact PI
Cell Model of Parkinson's Disease and Screening for Therapeutic Compounds$215,250
R21 · FY2008 · NS · contact PI
Therapeutic Neuroprotective Trials of Tiagabine in HD Mouse Models$215,250
R21 · FY2008 · NS · contact PI
Cell Model of Parkinson's Disease and Screening for Therapeutic Compounds$179,375
R21 · FY2007 · NS · contact PI
Therapeutic Neuroprotective Trials of Tiagabine in HD Mouse Models$179,238
R21 · FY2007 · NS · contact PI